Connection

Miguel Abboud to Anemia, Sickle Cell

Back to Details
This is a "connection" page, showing publications Miguel Abboud has written about Anemia, Sickle Cell.
Miguel Abboud
Connection Strength
11.007
Anemia, Sickle Cell
  1. Sickle cell disease care in Lebanon: resource-constrained and humanitarian crisis adaptations. Lancet Haematol. 2023 02; 10(2):e91-e92.
    View in: PubMed
    Score: 0.646
  2. Voxelotor for the treatment of sickle cell disease in pediatric patients. Expert Rev Hematol. 2022 06; 15(6):485-492.
    View in: PubMed
    Score: 0.618
  3. Emergence of gram-negative organisms as the cause of infections in patients with sickle cell disease. Pediatr Blood Cancer. 2021 01; 68(1):e28784.
    View in: PubMed
    Score: 0.553
  4. Interventions for preventing silent cerebral infarcts in people with sickle cell disease. Cochrane Database Syst Rev. 2020 04 06; 4:CD012389.
    View in: PubMed
    Score: 0.531
  5. Standard management of sickle cell disease complications. Hematol Oncol Stem Cell Ther. 2020 Jun; 13(2):85-90.
    View in: PubMed
    Score: 0.529
  6. Interventions for preventing silent cerebral infarcts in people with sickle cell disease. Cochrane Database Syst Rev. 2017 05 13; 5:CD012389.
    View in: PubMed
    Score: 0.435
  7. Sickle cell disease. Lancet. 2017 07 15; 390(10091):311-323.
    View in: PubMed
    Score: 0.426
  8. The Daily Experiences of Adolescents in Lebanon With Sickle Cell Disease. J Pediatr Health Care. 2015 Sep-Oct; 29(5):424-34.
    View in: PubMed
    Score: 0.374
  9. Educational intervention to improve the health outcomes of children with sickle cell disease. J Pediatr Health Care. 2015 Jan-Feb; 29(1):54-60.
    View in: PubMed
    Score: 0.359
  10. Intracranial blood flow velocities in patients with sickle cell disease and ?-thalassemia intermedia. Am J Hematol. 2013 Sep; 88(9):825.
    View in: PubMed
    Score: 0.336
  11. Pulmonary complications of sickle cell disease. Hemoglobin. 2011; 35(5-6):625-35.
    View in: PubMed
    Score: 0.295
  12. Cerebral infarction in children with sickle cell disease: a concise overview. Hemoglobin. 2011; 35(5-6):618-24.
    View in: PubMed
    Score: 0.295
  13. Discontinuing prophylactic transfusions increases the risk of silent brain infarction in children with sickle cell disease: data from STOP II. Blood. 2011 Jul 28; 118(4):894-8.
    View in: PubMed
    Score: 0.288
  14. Stem-cell transplantation in children and adults with sickle cell disease: an update. Expert Rev Hematol. 2011 Jun; 4(3):343-51.
    View in: PubMed
    Score: 0.288
  15. Safety and efficacy of high dose intravenous desferrioxamine for reduction of iron overload in sickle cell disease. Pediatr Blood Cancer. 2010 Dec 15; 55(7):1338-42.
    View in: PubMed
    Score: 0.279
  16. Pulmonary hypertension in children and young adults with sickle cell disease: evidence for familial clustering. Pediatr Blood Cancer. 2010 Mar; 54(3):398-402.
    View in: PubMed
    Score: 0.264
  17. Hematopoietic stem-cell transplantation for adults with sickle cell disease. N Engl J Med. 2009 Dec 10; 361(24):2380-1.
    View in: PubMed
    Score: 0.260
  18. Venous sinus thrombosis leading to stroke in a patient with sickle cell disease on hydroxyurea and high hemoglobin levels: treatment with thrombolysis. Am J Hematol. 2008 Oct; 83(10):818-20.
    View in: PubMed
    Score: 0.239
  19. Liver biopsy results in patients with sickle cell disease on chronic transfusions: poor correlation with ferritin levels. Pediatr Blood Cancer. 2008 Jan; 50(1):62-5.
    View in: PubMed
    Score: 0.227
  20. Prevention and management of strokes in patients with sickle cell disease. Curr Hematol Rep. 2006 Mar; 5(1):15-22.
    View in: PubMed
    Score: 0.200
  21. Radiographic predictors of neurocognitive functioning in pediatric Sickle Cell disease. J Child Neurol. 2006 Jan; 21(1):37-44.
    View in: PubMed
    Score: 0.198
  22. Magnetic resonance angiography in children with sickle cell disease and abnormal transcranial Doppler ultrasonography findings enrolled in the STOP study. Blood. 2004 Apr 01; 103(7):2822-6.
    View in: PubMed
    Score: 0.172
  23. Ticagrelor vs placebo for the reduction of vaso-occlusive crises in pediatric sickle cell disease: the HESTIA3 study. Blood. 2022 09 29; 140(13):1470-1481.
    View in: PubMed
    Score: 0.158
  24. Safety and efficacy of voxelotor in pediatric patients with sickle cell disease aged 4 to 11?years. Pediatr Blood Cancer. 2022 08; 69(8):e29716.
    View in: PubMed
    Score: 0.153
  25. Sevuparin for the treatment of acute pain crisis in patients with sickle cell disease: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Haematol. 2021 May; 8(5):e334-e343.
    View in: PubMed
    Score: 0.143
  26. Effect of Poloxamer 188 vs Placebo on Painful Vaso-Occlusive Episodes in Children and Adults With Sickle Cell Disease: A Randomized Clinical Trial. JAMA. 2021 04 20; 325(15):1513-1523.
    View in: PubMed
    Score: 0.143
  27. Impact of sickle cell disease on patients' daily lives, symptoms reported, and disease management strategies: Results from the international Sickle Cell World Assessment Survey (SWAY). Am J Hematol. 2021 04 01; 96(4):404-417.
    View in: PubMed
    Score: 0.141
  28. Pharmacokinetics and safety of ticagrelor in infants and toddlers with sickle cell disease aged <24?months. Pediatr Blood Cancer. 2021 05; 68(5):e28977.
    View in: PubMed
    Score: 0.141
  29. Paediatric to adult transition care for patients with sickle cell disease: a global perspective. Lancet Haematol. 2020 Apr; 7(4):e329-e341.
    View in: PubMed
    Score: 0.133
  30. Ticagrelor versus placebo for the reduction of vaso-occlusive crises in pediatric sickle cell disease: Rationale and design of a randomized, double-blind, parallel-group, multicenter phase 3 study (HESTIA3). Contemp Clin Trials. 2019 10; 85:105835.
    View in: PubMed
    Score: 0.127
  31. A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease. N Engl J Med. 2019 08 08; 381(6):509-519.
    View in: PubMed
    Score: 0.126
  32. Ticagrelor does not impact patient-reported pain in young adults with sickle cell disease: a multicentre, randomised phase IIb study. Br J Haematol. 2019 01; 184(2):269-278.
    View in: PubMed
    Score: 0.121
  33. Granulocytosis causing sickle-cell crisis. Lancet. 1998 Mar 28; 351(9107):959.
    View in: PubMed
    Score: 0.115
  34. Neurologic complications following bone marrow transplantation for sickle cell disease. Bone Marrow Transplant. 1996 Mar; 17(3):405-7.
    View in: PubMed
    Score: 0.100
  35. A Multinational Trial of Prasugrel for Sickle Cell Vaso-Occlusive Events. N Engl J Med. 2016 Feb 18; 374(7):625-35.
    View in: PubMed
    Score: 0.098
  36. 13-valent pneumococcal conjugate vaccine (PCV13) is immunogenic and safe in children 6-17 years of age with sickle cell disease previously vaccinated with 23-valent pneumococcal polysaccharide vaccine (PPSV23): Results of a phase 3 study. Pediatr Blood Cancer. 2015 Aug; 62(8):1427-36.
    View in: PubMed
    Score: 0.094
  37. Pain in children and adolescents with sickle cell anemia: a prospective study utilizing self-reporting. Am J Pediatr Hematol Oncol. 1994 Aug; 16(3):219-24.
    View in: PubMed
    Score: 0.090
  38. A double-blind, placebo-controlled phase II study of the efficacy and safety of 2,2-dimethylbutyrate (HQK-1001), an oral fetal globin inducer, in sickle cell disease. Am J Hematol. 2014 Jul; 89(7):709-13.
    View in: PubMed
    Score: 0.088
  39. Bone marrow transplantation for sickle cell disease. The United States experience. Am J Pediatr Hematol Oncol. 1994 Feb; 16(1):22-6.
    View in: PubMed
    Score: 0.087
  40. Bone marrow transplantation for sickle cell anemia. Am J Pediatr Hematol Oncol. 1994 Feb; 16(1):86-9.
    View in: PubMed
    Score: 0.087
  41. A dose-escalation phase IIa study of 2,2-dimethylbutyrate (HQK-1001), an oral fetal globin inducer, in sickle cell disease. Am J Hematol. 2013 Nov; 88(11):E255-60.
    View in: PubMed
    Score: 0.085
  42. Effect of chronic transfusion therapy on progression of neurovascular pathology in pediatric patients with sickle cell anemia. Blood Cells Mol Dis. 2011 Aug 15; 47(2):125-8.
    View in: PubMed
    Score: 0.072
  43. Y-chromosome R-M343 African lineages and sickle cell disease reveal structured assimilation in Lebanon. J Hum Genet. 2011 Jan; 56(1):29-33.
    View in: PubMed
    Score: 0.069
  44. Vascular at-risk genotypes and disease severity in Lebanese sickle cell disease patients. Am J Hematol. 2010 May; 85(5):395-6.
    View in: PubMed
    Score: 0.067
  45. Serum ferritin level changes in children with sickle cell disease on chronic blood transfusion are nonlinear and are associated with iron load and liver injury. Blood. 2009 Nov 19; 114(21):4632-8.
    View in: PubMed
    Score: 0.064
  46. Sickle cell disease at the dawn of the molecular era. Hemoglobin. 2009; 33 Suppl 1:S93-S106.
    View in: PubMed
    Score: 0.061
  47. Transfusion prevents acute chest syndrome predicted by elevated secretory phospholipase A2. Br J Haematol. 2007 Jan; 136(2):343-4.
    View in: PubMed
    Score: 0.053
  48. Renal kallikrein: a risk marker for nephropathy in children with sickle cell disease. J Pediatr Hematol Oncol. 2006 Mar; 28(3):147-53.
    View in: PubMed
    Score: 0.050
  49. Secretory phospholipase A2 levels in patients with sickle cell disease and acute chest syndrome. Hemoglobin. 2006; 30(2):165-70.
    View in: PubMed
    Score: 0.049
  50. Safety of purified poloxamer 188 in sickle cell disease: phase I study of a non-ionic surfactant in the management of acute chest syndrome. Hemoglobin. 2004 May; 28(2):85-102.
    View in: PubMed
    Score: 0.044
  51. Stroke and conversion to high risk in children screened with transcranial Doppler ultrasound during the STOP study. Blood. 2004 May 15; 103(10):3689-94.
    View in: PubMed
    Score: 0.043
  52. Transcranial Doppler ultrasonography and neurocognitive functioning in children with sickle cell disease. Pediatrics. 2003 Aug; 112(2):324-31.
    View in: PubMed
    Score: 0.042
  53. Impact of chronic transfusion on incidence of pain and acute chest syndrome during the Stroke Prevention Trial (STOP) in sickle-cell anemia. J Pediatr. 2001 Dec; 139(6):785-9.
    View in: PubMed
    Score: 0.037
  54. Multicenter comparison of magnetic resonance imaging and transcranial Doppler ultrasonography in the evaluation of the central nervous system in children with sickle cell disease. J Pediatr Hematol Oncol. 2000 Jul-Aug; 22(4):335-9.
    View in: PubMed
    Score: 0.034
  55. Bone marrow transplantation versus periodic prophylactic blood transfusion in sickle cell patients at high risk of ischemic stroke: a decision analysis. Blood. 2000 May 15; 95(10):3057-64.
    View in: PubMed
    Score: 0.033
  56. Costs, charges, and reimbursements for persons with sickle cell disease. J Pediatr Hematol Oncol. 1999 Sep-Oct; 21(5):389-96.
    View in: PubMed
    Score: 0.032
  57. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med. 1998 Jul 02; 339(1):5-11.
    View in: PubMed
    Score: 0.029
  58. Stroke prevention trial in sickle cell anemia. Control Clin Trials. 1998 Feb; 19(1):110-29.
    View in: PubMed
    Score: 0.029
  59. Renal Medullary Carcinoma: Establishing Standards in Practice. J Oncol Pract. 2017 07; 13(7):414-421.
    View in: PubMed
    Score: 0.027
  60. Cholecystectomy in sickle cell anemia patients: perioperative outcome of 364 cases from the National Preoperative Transfusion Study. Preoperative Transfusion in Sickle Cell Disease Study Group. Blood. 1997 Mar 01; 89(5):1533-42.
    View in: PubMed
    Score: 0.027
  61. A comparison of conservative and aggressive transfusion regimens in the perioperative management of sickle cell disease. The Preoperative Transfusion in Sickle Cell Disease Study Group. N Engl J Med. 1995 Jul 27; 333(4):206-13.
    View in: PubMed
    Score: 0.024
  62. Risk of recurrent stroke in patients with sickle cell disease treated with erythrocyte transfusions. J Pediatr. 1995 Jun; 126(6):896-9.
    View in: PubMed
    Score: 0.024
  63. Impact of laparoscopic cholecystectomy on the management of cholelithiasis in children with sickle cell disease. J Pediatr Surg. 1994 Feb; 29(2):209-12; discussion 212-3.
    View in: PubMed
    Score: 0.022
  64. Acute chest syndrome in sickle cell disease: CT evidence of microvascular occlusion. Radiology. 1993 Apr; 187(1):45-9.
    View in: PubMed
    Score: 0.020
  65. Chemical and functional analysis of generic hydroxyurea formulations. Pediatr Hematol Oncol. 2008 Jun; 25(5):423-9.
    View in: PubMed
    Score: 0.015
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.